pelabresib

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Advanced MalignanciesMyelofibrosis

53 competitors in Advanced Malignancies

#DrugCompanyPhaseTrials

1

Lenvima

Eisai

Phase 3

22

Elunate

Takeda

Phase 3

13

Zaniducla

Jazz Pharmaceuticals

Phase 3

14

Talzenna

Pfizer

Phase 3

15

Beyfortus

BeiGene

Phase 3

16

Alimta

SShawn Eagle

Phase 3

57

Keytruda

Merck & Co.

Phase 2

148

Bavencio

EMD Serono

Phase 3

39

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

110

Inlyta

PPrism Pharmaceuticals

Phase 3

1Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Advanced Malignancies3 trials

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Completed·CConstellation Pharmaceuticals·Phase 1·NCT05391022·35 enrolled

A Phase 1b, Open Label, 2-Part Study to Evaluate the Effect of Pelabresib (DAK539/CPI-0610) on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Patients With Advanced Malignancies

Recruiting·Novartis·Phase 1·NCT07340190·24 enrolled

A Phase 1b, Open-Label, Multicenter Study to Evaluate the Pharmacokinetic Profile of Pelabresib (DAK539/CPI-0610) in Patients With Advanced Malignancies and Hepatic Impairment

Recruiting·Novartis·Phase 1·NCT07422610·24 enrolled

Primary Myelofibrosis (PMF)2 trials

A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive

Recruiting·Novartis·Phase 3·NCT07357727·460 enrolled

A Phase 1b Study of Pelabresib (DAK539) add-on to Stable Dose of Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Active, not recruiting·Novartis·Phase 1·NCT07340138·3 enrolled

Malignancies1 trial

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Completed·CConstellation Pharmaceuticals·Phase 1/2·NCT02158858·336 enrolled

Myelofibrosis1 trial

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

Active, not recruiting·Novartis·Phase 3·NCT04603495·430 enrolled

Unspecified2 trials

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Recruiting·Novartis·Phase 3·NCT06401356·50 enrolled

A Phase 1, Two-part, Open-label, Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants

Not yet recruiting·Novartis·Phase 1·NCT07783503·30 enrolled

Details

Drug Info

Related News